RMD ResMed Inc.

Company Profile for ResMed

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.

 
Company: ResMed
 
Headquarters Address: 9001 Spectrum Center Blvd.
San Diego, CA
 
Main Telephone: 800.424.0737
 
Website:

http://newsroom.resmed.com

 
Ticker: (NYSE:RMD)
(ASX:RMD)
 
Type of Organization: Public
 
Industry: Medical Devices
 
Earnings Release Dates: 3rd Quarter: April 26, 2018
 
Key Executives: CEO: Mick Farrell
 
Public Relations
Contact: Jayme Rubenstein
Phone: 858.836.6798
Email:

[email protected]

 
Investor Relations
Contact: David Pendarvis
Phone: 858.836.5983
Email:

[email protected]

 

EN
06/04/2018

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024 SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  • Location: • Date:Thursday, April 25, 2024 • Time:1:30 p.m. PDT ...

April 4, 2024 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis 36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and othe...

March 15, 2024 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Introducing the AirFit F40: Experience Unprecedented Freedom with the ...

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask.Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred positio...

March 6, 2024 1 EN
Free Trial
RMD RESMED INC.

ResMed Inc: 1 director

A director at ResMed Inc sold 23,535 shares at 182.664USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

02/24/24 February 24, 2024 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers ...

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapyPart of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: ...

February 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch